RCT for the Chinese Medicine in Treating Hypercholesterolemia
Status:
NOT_YET_RECRUITING
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled clinical trial. Eligible subjects will randomized into a treatment group or placebo group. They will receive either Chinese medicine granules or placebo granules for 8 weeks followed by a 4-week observation period. The primary outcome would be the percent change in Low-density lipoprotein cholesterol levels (LDL-C) after treatment.